Maxillary Sinusitis as a Surrogate Model for CF Gene Therapy Clinical Trials in Patients with Antrostomies

Journal of Gene Medicine

Volumn 1, Issue 1, 1999, Pages 13-21

  Wagner, John A ^a   Nepomuceno, Ilynn B ^a   Shah, Niraj ^a   Messner, Anna H ^a   Moran, Mary Lynn ^a   Norbash, Alexander M ^a   Moss, Richard B ^a   Wine, Jeffrey J ^b   Gardner, Phyllis ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Clinical trial; Cystic fibrosis; Gene therapy; Maxillary sinus; Sinusitis; Surrogate model

Indexed keywords

ADENO-ASSOCIATED VIRUS; BACTERIA (MICROORGANISMS);

ADULT; ARTICLE; BIOLOGICAL MODEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; MALE; MAXILLA SINUSITIS; MAXILLARY SINUS; MICROBIOLOGY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ADULT; CYSTIC FIBROSIS; FEMALE; GENE THERAPY; HUMANS; MALE; MAXILLARY SINUS; MAXILLARY SINUSITIS; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032599949     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-2254(199901/02)1:1<13::AID-JGM6>3.3.CO;2-7     Document Type: Article

References (28)

1. Ramsey BW, Boat F, Accurso F, et al. Outcome measures for clinical trials in cystic fibrosis: Summary of a cystic fibrosis foundation consensus conference. J Pediatr 1994; 124: 177-192.
2. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997; 41: 161-165.
3. Caplen NJ, Alton EW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995; 1: 39-46.
4. Graham SM, Launspach JL. Utility of the nasal model in gene transfer studies in cystic fibrosis. Rhinology 1997; 35: 149-153.
5. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995; 6: 445-455.
6. Zabner J, Couture LA, Gregory RJ, et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75: 207-216.
7. Wagner JA, Wagner JA, Moran ML, et al. A Phase I/II Study of tgAAV-CF for the Treatment of Chronic Sinusiris in Patients with Cystic Fibrosis. Hum Gene Ther 1998; 9: 889-909.
8. Wine JJ, King W, Lewiston NJ. Method for rapid evaluation of topically applied agents to cystic fibrosis airways. Am J Physiol 1991; 261: L218-221.
9. Moss RB, King W. Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery. Arch Otolaryngol Head Neck Surg 1995; 121: 566-572.
10. Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 1998; 351: 1702-1703.
11. Wagner JA, Messner AH, Moran ML, et al. Safety and biological effecacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999, in press.
12. Wagner JA, Gardner P. Toward cystic fibrosis gene therapy. Annu Rev Med 1997; 48: 203-216.
13. Riordan JR, Rommens JM, Kerem B-S, et al. Indentification of the cystic fibrosis gene: cloning and characterisation of the comlementary DNA. Science 1989; 245: 1066-1073.
14. Drumm ML, Pope HA, Cliff WH, et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 1990; 62: 1227-1233.
15. Rich DP, Anderson MP, Gregory RJ, et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990; 347: 358-363.
16. Hyde SC, Gill DR, Higgins CF, et al. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 1993; 362: 250-255.
17. Zhou L, Dey CR, Wert SE, et al. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 1994; 266: 1705-1708.
18. Johnson LG, Olsen JC, Sarkadi B, et al. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992; 2: 21-25.
19. Johnson LG, Boyles SE, Wilson J, Boucher RC. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995; 95: 1377-1382.
20. Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995; 333: 823-831.
21. Crystal RG, McElvaney NG, Rosenfeld MA, et al Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
22. Bellon G, Michel-Calemard L, Thouvenot D, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial. Hum Gene Ther 1997; 8: 15-26.
23. Cepero R, Smith RJ, Catlin FI, et al. Cystic fibrosis -an otolaryngologic perspective. Otolaryngol Head Neck Surg 1987; 97: 356-360.
24. Rosenfeld RM. Pilot study of outcomes in pediatric rhinosinusitis. Arch Otolaryngol Head Neck Surg 1995; 121: 729-736.
25. Cuyler JP, Monaghan AJ. Cystic fibrosis and sinusitis. J Otolaryngol 1989; 18: 173-175.
26. Davidson TM, Murphy C, Mitchell M, Smith C, Light M. Management of chronic sinusitis in cystic fibrosis. Laryngoscope 1995; 105: 354-358.
27. Lewiston N, King V, Umetsu D, et al. Cystic fibrosis patients who have undergone heart-lung transplantation benefit from maxillary sinus antrostomy and repeated sinus lavage. Transplant Proc 1991; 23: 1207-1208.
28. Welsh MJ, Zabner J, Graham SM, et al Adenovirus-mediated gene transfer for cystic fibrosis: Part A. Safety of dose and repeat administration in the nasal epithelium. Part B. Clinical efficacy in the maxillary sinus. Hum Gene Ther 1995; 6: 205-218.